Search results for Moderna
Industry
Moderna, Merck personalised mRNA cancer vaccine cuts melanoma recurrence or death risk by 42%
A personalised mRNA cancer vaccine being co-developed by Moderna and Merck reduced the risk of recurrence or death in melanoma patients by 42%, the report said. In a phase 3 trial involving 1,137 patients who had tumours removed by surgery, those receiving the vaccine intismeran with Merck\'s Keytruda outperformed a Keytruda-plus-placebo group. The companies are discussing approval procedures with regulators, with detailed results due at a European oncology meeting in Madrid.
Industry
Moderna jumps nearly 7% ahead of Nasdaq 100 inclusion; Citi warns of \'sell\'
Moderna shares jumped nearly 7% ahead of its scheduled inclusion in the Nasdaq 100 before the market opens on Oct. 9, closing at $203.21. The stock neared its 52-week high after rising to $205.77 intraday. Tokenised shares also gained, though they trade separately from Nasdaq hours. Moderna began management changes, with COO Juan Andres returning to a newly created role and CTO and quality chief Jerh Collins retiring. Citi downgraded the stock to sell.
AI & Enterprise
AI fear-battered stocks revive in August U.S. market rebound lineup
In August, U.S. stocks that had been weighed down by Wall Street’s bearish narratives rebounded sharply, CNBC reported. Jim Cramer said worries over AI threats, slower growth and worsening conditions were overturned by earnings and shifts in positioning. Moderna surged after reporting promising results for an experimental melanoma vaccine with Merck. Enterprise software names rebounded as a high-leverage hedge fund unwound bets. Other gainers included Gartner, Newmont, Paramount Skydance, Super Micro Computer, Sandisk and Coinbase.